Juno Therapeutics

Juno Therapeutics is a Celgene company. Please follow @Celgene for news and updates. Read our guidelines:

[Juno Therapeutics @JunoThera]

Today we welcomed Dr. Leslie S. Kean, Associate Director, Ben Towne Center for Childhood Cancer Research @seattlechildren to learn how she is working to solve the mystery of immune recognition and immune tolerance. #womeninscience

[Juno Therapeutics @JunoThera]

This Sunday, Feb 11th, is International Day of Women and Girls in Science. Juno is proud to support #WomeninScience! Check out @WomenScienceDay to learn more and see events happening around the world.

[Juno Therapeutics @JunoThera]

We were thrilled to welcome @ClaireShipman to Juno to discuss how confidence drives career development and impact.

[Juno Therapeutics @JunoThera]

Juno Names Cindy Elkins Chief Information Officer: https://t.co/OkGtp9nFdh

[Juno Therapeutics @JunoThera]

On behalf of our employees, we'd like to wish everyone a very happy holiday and healthy new year!

[Juno Therapeutics @JunoThera]

Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH. Read more: https://t.co/CSv3JrvDDk

[Juno Therapeutics @JunoThera]

There's still time to stop by Booth #523 to learn more about our pipeline. #ASH17 Impt info: https://t.co/MdDutgO5qk

[Juno Therapeutics @JunoThera]

Today we announced updated results from the TRANSCEND study of JCAR017 in non-Hodgkin lymphoma https://t.co/O1hp2Warf9 Impt. Info: https://t.co/MdDuth5GOU

[Juno Therapeutics @JunoThera]

Juno highlights key translational insights with JCAR017 in patients with DLBCL. Read more here: https://t.co/bSYmqpDJMY

[Juno Therapeutics @JunoThera]

Curious about Juno's #ASH17 presentations? Find out our schedule here: https://t.co/h6vcmtKu2R Impt. Info: https://t.co/MdDutgO5qk

[Juno Therapeutics @JunoThera]

Juno will have 9 presentations at #ASH17. Learn more at https://t.co/h6vcmu25rr Impt. Info: https://t.co/MdDuth5GOU

[Juno Therapeutics @JunoThera]

Juno signs agreements with Eli Lilly, OncoTracker and @FredHutch to advance multiple myeloma program: https://t.co/WuV4VRVA6I

[Juno Therapeutics @JunoThera]

We're one week out from #ASH17 - Take a look at the schedule of our presentations and join us in Atlanta: https://t.co/h6vcmtKu2R Impt. Info: https://t.co/MdDutgO5qk

[Juno Therapeutics @JunoThera]

Juno appoints Ann L. Lee as EVP of Technical Operations and Patrick Y. Yang as EVP, Senior Advisor to the CEO https://t.co/8oj8X2OMLM

[Juno Therapeutics @JunoThera]

#tbt Remembering the September opening of our new #Seattle #HQ #400Dexter #changingmedicineforgood #CAR_T Impt. info: https://t.co/MdDutgO5qk https://t.co/3Uyp4dosYH

[Juno Therapeutics @JunoThera]

Today @JunoThera releases 3Q17 results and update on new data from JCAR017. Read more here: https://t.co/20fS0J85r9

[Juno Therapeutics @JunoThera]

Juno to highlight new advances in CD19- and BCMA-targeted CAR T therapy at #ASH17: https://t.co/x1KJhIfpD0

[Juno Therapeutics @JunoThera]

Rain didn’t stop us last night from supporting @LLSusa @LTN_WA for #BloodCancer #research. @LLSwaak

[Juno Therapeutics @JunoThera]

Congratulations to @GileadSciences & @KitePharma. Every approved #CAR_T is a positive step in the fight against cancer.

[Juno Therapeutics @JunoThera]

Dr. Rebecca Gardner of @seattlechildren discusses CAR T findings in children with r/r CD19+ ALL. Impt info: https://t.co/K3tzdrWiOv